As previously reported, Wedbush analyst Yun Zhong added Outperform-rated Wave Life Sciences (WVE) to the firm’s Best Ideas List and raised the price target on the stock to $33 from $20 following the positive initial WVE-007 Phase 1 data in obesity. Additional data from higher dose cohorts in Q1 and Q2 2026 could show further improved weight reduction with good muscle preservation, and the WVE-006 clinical update in alpha-1 antitrypsin deficiency in Q1 2026 and NDA submission for WVE-N531 in Duchenne muscular dystrophy should provide additional catalysts, Wedbush argues.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE: